ASCO GI 2024
ASCO GI 2024
Advertisement
Emily MenendezASCO GI 2024 | February 7, 2024
In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1.
Read More
Emily MenendezASCO GI 2024 | February 7, 2024
Meta-analysis data has shown that HAIP combined with systemic chemotherapy can provide a pooled 3-year OS rate of 39.5%.
Amit Mahipal, MDASCO GI 2024 | January 31, 2024
Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing.
Ethan Ludmir, MDASCO GI 2024 | January 25, 2024
Dr. Ethan Ludmir discusses the phase II EXTEND trial on MDT with systemic therapy for pancreatic ductal adenocarcinoma.
Elizabeth Conner, MDASCO GI 2024 | January 25, 2024
Dr. Elizabeth Conner offers insight on how DCP can be utilized as a biomarker for treatment response in patients with HCC.
Christopher Lieu, MDASCO GI 2024 | January 25, 2024
Dr. Lieu discusses the CIRCULATE-NORTH AMERICA trial on ctDNA status as a biomarker for risk stratification in colon cancer.
Timothy Brown, MDASCO GI 2024 | January 29, 2024
Dr. Brown discussed the results of a retrospective analysis on the addition of radiation to atezolizumab and bevacizumab.
Yelena Janjigian, MDASCO GI 2024 | January 25, 2024
Dr. Yelena Janjigian discusses the results of the phase 3 MATTERHORN study at ASCO GI 2024.
Milind Javle, MDASCO GI 2024 | January 25, 2024
Dr. Milind Javle discusses tinengotinib monotherapy in patients with metastatic cholangiocarcinoma at ASCO GI 2024.
Emily MenendezASCO GI 2024 | January 23, 2024
First-line nivolumab plus ipilimumab can act as a beneficial standard-of-care option for patients with MSI-H/dMMR mCRC.
Emily MenendezASCO GI 2024 | January 23, 2024
NETTER-2 is the first randomized study to demonstrate the efficacy of RLT as a 1L treatment for any form of cancer.
Emily MenendezASCO GI 2024 | January 23, 2024
Durvalumab plus bevacizumab with TACE demonstrated significantly improved PFS rates over TACE monotherapy.
Emily MenendezASCO GI 2024 | January 23, 2024
At ASCO GI 2024, new research examined several treatment combinations to determine which combination may improve OS rates.
Emily MenendezASCO GI 2024 | January 23, 2024
The ESCORT-NEO study explored the use of neoadjuvant camrelizumab with chemotherapy followed by adjuvant camrelizumab.
Emily MenendezASCO GI 2024 | January 23, 2024
A new report detailed the results of the LEAP-002 study following 12 months of additional follow-up.
Katy MarshallASCO GI 2024 | January 23, 2024
In 35 patients, the Eastern Cooperative Oncology Group performance status (ECOG-PS) was 0.
Zachary BessetteASCO GI 2024 | January 23, 2024
An analysis of demographic, clinical characteristics, and treatment patterns for HCC for defining early-stage disease.
Katy MarshallASCO GI 2024 | January 23, 2024
Prior research shows select patients with mCRC endure longer response to regorafenib while in clinical care settings.
Zachary BessetteASCO GI 2024 | January 23, 2024
A novel combination regimen involving serplulimab may be a promising first-line treatment option for patients with mCRC.
Katy MarshallASCO GI 2024 | January 23, 2024
A subanalysis of the GENESECT study analyzed data from 50 gemcitabine monotherapy patients.
Advertisement
Advertisement
Advertisement
Latest News

February 28, 2024